Ona Therapeutics
Founded 2019 · 41 employees on LinkedIn · 9 known investors
Ona Therapeutics develops therapeutic antibodies targeting lipid metabolism to treat advanced and metastatic cancers, including liposarcoma. The company is a Spanish biotech firm focused on oncology with support from European and Spanish government research funding programs.
Investors · 9
Fund+Leuven · $5.5M – $16.5M
KorysHalle · $5.4M
Mérieux Equity PartnersParis · $3.2M – $86M
Ysios CapitalBarcelona · $5.4M – $21.6M
Alta Life SciencesreportedBarcelona
Asabys Partnersreported · 2 sourcesMadrid
BpifrancereportedParis, Ile-De-France · $270K
CDTIreportedMadrid
Columbus Venture PartnersreportedValencia
Funding
SEC filings, press & company announcements$86.6M disclosed across 1 round · 2026
- $86.6MSeries BJun 2026 · 4 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Fierce Biotech Fundraising Tracker '26: InduPro assembles $77M; Vaderis nets $152M series Bfiercebiotech.com · Aug 2026Frequently asked questions
- What does Ona Therapeutics do?
- Ona Therapeutics develops therapeutic antibodies targeting lipid metabolism to treat advanced and metastatic cancers, including liposarcoma. The company is a Spanish biotech firm focused on oncology with support from European and Spanish government research funding programs.
- Who are Ona Therapeutics's investors?
- Ona Therapeutics's investors include Fund+, Korys, Mérieux Equity Partners, Ysios Capital, Alta Life Sciences, Asabys Partners, Bpifrance, CDTI and 1 more.
- How much funding has Ona Therapeutics raised?
- Ona Therapeutics has disclosed $86.6M raised across 1 round.